A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Trial Profile

A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Masitinib (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 04 Jan 2018 According to an AB Science media release, final results of the study are expected in Q2 2019.
    • 04 Jan 2018 According to an AB Science media release, based on interim analysis (50% of patients having reached the 96 week treatment duration), Independent Data Safety Monitoring Committee (IDMC) has recommended the continuation of the study with no increment in the study population.
    • 21 Sep 2017 This trial has been suspended in Slovakia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top